Published in Ther Adv Med Oncol on September 01, 2010
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol (2001) 5.59
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res (2007) 3.49
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol (2009) 3.28
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol (2009) 2.31
Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood (2001) 2.27
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 2.23
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis (2005) 2.12
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol (1997) 1.98
Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev (2009) 1.88
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol (2007) 1.86
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol (2001) 1.58
Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol (2001) 1.57
Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res (2000) 1.55
Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol (2001) 1.54
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol (1998) 1.47
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer (1998) 1.38
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res (2006) 1.33
Retracted Neoplastic meningitis. J Clin Oncol (2005) 1.32
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer (2006) 1.31
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res (2008) 1.27
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis (2005) 1.16
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res (2009) 1.10
VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol (2009) 1.09
Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer (2004) 1.08
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res (2009) 1.07
Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res (2008) 1.07
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother (2008) 1.02
Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Relat Cancer (2006) 1.01
Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer (2009) 0.97
Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol (2015) 0.94
Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis (2004) 0.92
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol (2009) 0.91
Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science (1982) 0.91
Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res (2005) 0.90
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol (2009) 0.85
Soft tissue sarcoma in adults. Curr Opin Oncol (1997) 0.81
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer (1999) 1.81
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res (1998) 1.80
Blood platelets and serum VEGF in cancer patients. Br J Cancer (1999) 1.66
Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer (2009) 1.55
Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer (2010) 1.54
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer (1997) 1.54
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51
Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer (2006) 1.46
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer (2004) 1.44
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat (2004) 1.43
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer (2003) 1.33
Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer (2007) 1.17
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol (1996) 1.16
Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer (2006) 1.15
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer (2009) 1.13
The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer (2009) 1.09
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol (1999) 1.09
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am (1999) 1.08
Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology (2003) 1.07
NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer (2007) 1.06
Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer (2004) 1.00
A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology (2007) 0.98
Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol (1997) 0.98
Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern-dependent. Histopathology (2002) 0.98
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer (2005) 0.97
Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer (2006) 0.96
Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer. J Pathol (2007) 0.95
Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer (2008) 0.95
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol (1994) 0.95
Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis. Br J Dermatol (2014) 0.94
Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst (1995) 0.91
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncol Rep (2011) 0.90
High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer (2007) 0.89
Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol (2004) 0.88
Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer. Br J Cancer (2011) 0.88
Growth index is independent of microvessel density in non-small cell lung carcinomas. Hum Pathol (2003) 0.85
In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs (1997) 0.83
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer (2000) 0.82
Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. J Natl Cancer Inst (1997) 0.81
Growth pattern of colorectal liver metastasis as a marker of recurrence risk. Clin Exp Metastasis (2015) 0.81
Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications. Br J Dermatol (2014) 0.80
The use of rectus abdominis myocutaneous flaps following excision of vulvar cancer. Br J Obstet Gynaecol (1990) 0.80
VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. Clin Transl Oncol (2011) 0.78
Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147-3152, 2000. Clin Cancer Res (2001) 0.78
Heterogeneity of vascularisation in invasive breast carcinoma. Eur J Cancer (2002) 0.77
Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem Biophys Res Commun (2006) 0.77
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer Microenviron (2015) 0.76
Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth. Br J Cancer (2009) 0.76
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance. Virchows Arch (2004) 0.76
High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis Group. Br J Cancer (1996) 0.75
5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Cancer (1995) 0.75
Alpha-interferon (IFN) in the treatment of metastatic carcinoid tumors. Cancer (1991) 0.75
Microvascular count and prognosis in colorectal cancer. J Clin Oncol (1996) 0.75
Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect? Anticancer Drugs (1996) 0.75
Early vulval cancer: the place of conservative management. Eur J Surg Oncol (1993) 0.75
Comparative analysis of the biochemical and immunohistochemical determination of hormone receptors in invasive breast carcinoma influence of the tumor-stroma ratio. Pathol Res Pract (2002) 0.75
The rising incidence of heterotopic pregnancy: two case reports. Eur J Obstet Gynecol Reprod Biol (1987) 0.75